Brookline Capital Acquisition Shares Resume Trading, Up 27%
$BCAC
Consumer Electronics/Appliances
Industrials
Brookline Capital Acquisition Shares Resume Trading, Up 27%
Save time and jump to the most important pieces.
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
- Healthcare institutional investors and insiders commit $15 million through private investment in public equity ("PIPE") - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the Phase 2 development of Apexigen's lead asset, sotigalimab, a CD40 agonist antibody with first-in-class and best-in-class potential - - Merger expected to be completed in July 2022; combined company expected to be listed on Nasdaq under the ticker symbol "APGN" - - Joint investor conference call to discuss the proposed transaction today, Friday, March 18, 2022 at 8:30 a.m. ET - SAN CARLOS, Calif. and NEW YORK, March 18, 2022
SC 13G - Apexigen, Inc. (0001814140) (Subject)
SC 13G/A - Brookline Capital Acquisition Corp. (0001814140) (Subject)
SC 13G - Brookline Capital Acquisition Corp. (0001814140) (Subject)
10-Q - Apexigen, Inc. (0001814140) (Filer)
8-K - Apexigen, Inc. (0001814140) (Filer)
S-8 - Apexigen, Inc. (0001814140) (Filer)
SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Apexigen's Management will participate in the Brookline Capital Markets Newport Symposium, to be held in Newport, Rhode Island on Monday, July 18, 2022. Brookline Capital Markets Newport SymposiumFormat: Apexigen presentation and 1-on-1 meetingsDate: Monday, July 18, 2022Location: Newport, Rhode Island Please contact your Brookline Capital Markets sales representative for additional information. About Apexigen, Inc.Apexigen is a clinical-st
SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp
SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon
Gainers Getty Images Holdings, Inc. (NYSE:GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal Holdings (CCNB). Brookline Capital Acquisition Corp. (NASDAQ:BCAC) gained 127.3% to settle at $22.71. AMTD Digital Inc. (NYSE:HKD) surged 122.4% to settle at $400.25 on continued post-IPO volatility. Senti Biosciences, Inc. (NASDAQ:SNTI) climbed 68.3% to close at $3.13 after declining 5% on Thursday. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) gained 51.6% to close at $0.7930. The U.S. Food and Drug Administration (FDA) recently declined to issue an Emergency Use Authorization (EUA) for NRx Pharmaceu
During Friday's session, 61 companies made new 52-week lows. Areas of Interest About Today's 52-Week Lows: Verizon Communications (NYSE:VZ) was the biggest company in terms of market cap to set a new 52-week low. Kiora Pharmaceuticals (NASDAQ:KPRX) is the smallest company on a market cap basis to set a new 52-week low. VistaGen Therapeutics (NASDAQ:VTGN) saw the most significant move of the companies, as shares traded down 85.49% to reach its new 52-week low. Shapeways Hldgs (NYSE:SHPW) shares rebounded the highest, with shares trading up 0.16%, bouncing back after reaching its new 52-week low. During thn Friday, the following stocks set new 52-week lows: Verizon Communication
SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp
SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon